This milestone underscores the power of Guardant Health’s InfinityAI platform and real-world data to enable innovative evidence generation in rare biomarker-defined populations
Why Guardant Health (GH) Stock Is Falling Today
3 Growth Stocks We Think Twice About
Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development
3 Reasons to Avoid GH and 1 Stock to Buy Instead
Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoring Studies show strong...
Partnership marks the first introduction of Shield ™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines ...
Survey highlights barriers to colorectal cancer screening for adults 45 and over Overwhelming majority (92%) of Americans ages 45 and over believe blood-based...
Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network ...
1 Russell 2000 Stock on Our Watchlist and 2 We Question